Monday Mornings Just Got Interesting

At 10x Earnings, Is LULU Cheap or Broken?

Hey there, bargain hunter. Before you get excited about a former high-flyer trading at 10 times forward earnings, you need to answer one question first: is the “E” in that P/E ratio actually going to hold?

Scoreboard

Lululemon reports fiscal Q2 2026 after the close on September 3. Management guided Q2 EPS to $1.76-$1.81, against $3.10 in the year-ago quarter. That is about a 42% year-over-year drop, with operating margin targeted at approximately 11.6% versus 20.7% a year ago. Full-year EPS was cut to $10.95-$11.15 from $13.26 in fiscal 2025. The stock sits far below its all-time high. Welcome to value-screen territory.

The Real Issue: Is the Earnings Floor Real?

At roughly 10-11 times forward earnings, LULU screens cheap against Nike’s forward multiple, which is materially higher. The problem is that UBS, heading into the Q2 report, expects management to cut full-year EPS guidance again, this time to around $9.70-$9.90, below current Wall Street consensus estimates. If that cut materializes, the “cheap” multiple changes fast because the denominator just got smaller.

That is the trap. A stock is not cheap because the multiple is low. It is cheap when the earnings number stops falling. LULU has not yet proven that.

What the Business Is, and How It Makes Money

Lululemon sells premium athletic apparel, primarily direct-to-consumer through company-owned stores and e-commerce. That model produced historically elite gross margins above the high-50s and return on equity above 30%. The company has generated more than $1 billion in annual free cash flow in recent periods. On those balance-sheet metrics alone, this is not a broken company.

What is broken, or at least badly bent, is North America. Q1 comparable sales in the Americas fell 5% (6% on a constant-dollar basis). China Mainland is a genuine offset, with Q1 revenue up 30%, and full-year guidance calling for approximately 20% growth there, but China Mainland represented about 16% of revenue in fiscal 2025. It cannot rescue the income statement on its own.

The Two Numbers That Make or Break the Case

Two data points on September 3 will determine whether LULU is cheap or value-trapped:

• Inventory on a unit basis. At the end of Q1, dollar inventories were up 2% to $1.7 billion, but units were down 4%. That is the right direction. If Q2 shows units continuing to decline or hold flat against revenue, it signals the markdown cycle is manageable. If units inflate while revenue shrinks, you have a clearance problem, not a repositioning.
• Full-price sell-through trajectory. Management said Q1 showed a sequential improvement in full-price sales, with full-price sales up high-single-digits in the quarter. If full-price momentum is decelerating rather than building, the margin pressure will be harder to unwind in the back half of fiscal 2026 the way management implies.

Is It Actually Cheap?

Lululemon’s forward PE of roughly 10-11 times sits well below where high-quality branded retailers often trade in healthier cycles. Its EV/EBITDA is also compressed versus its own history. Nike, which is itself in turnaround mode, trades at a materially higher forward earnings multiple. On that comparison alone, LULU can look inexpensive.

But the valuation only works if EPS stabilizes. FY25 EPS was $13.26. Full-year FY26 guidance is $10.95-$11.15. UBS thinks the real number lands closer to $9.70-$9.90. A company multiple guidance cuts into a down-cycle deserves skepticism, not a growth multiple.

Bull, Base, Bear

• Bull: New CEO Heidi O’Neill, a former Nike executive with more than 25 years at the brand, starts September 8, five days after earnings. Her product and brand reset expertise could stabilize the North American traffic decline by mid-2027. China continues at 20% growth. Gross margin recovers 150-200bp as markdowns normalize in H2. Stock re-rates toward 14-15 times FY27 EPS.
• Base: EPS guidance gets cut modestly to the $9.70-$10 range on September 3. North America comps stay negative through year-end. The stock treads water at current levels while the market waits on O’Neill’s first strategic moves. Free cash flow keeps the balance sheet sound.
• Bear: Full-price sell-through stalls. Inventory units creep higher. Alo Yoga and Vuori accelerate market-share gains in the core women’s segment. Another round of markdowns in Q3 takes gross margin below 52%, and FY27 EPS estimates follow FY26 into the cut cycle. Stock revisits the $70-$80 range.

Action Plan

Do not buy the whole position before September 3. This is a data-dependent situation and the data arrives in five days. If the report shows units down, full-price sales improving sequentially, and EPS guidance not cut below $9.70, a starter position at current prices makes sense. Scale in a second tranche after O’Neill’s first investor day, likely in early 2027. If inventory units balloon and full-year EPS guidance drops below $9.50, step aside: the floor is not in.

Cheap Investor Checklist

• Q2 inventory units: flat or declining year-over-year? (Must see yes)
• Full-price sell-through: sequential improvement vs. Q1? (Must see yes)
• Q2 gross margin: any downside surprise vs. guidance? (Watch closely)
• FY26 EPS guidance: does it hold above $9.70? (Line in the sand)
• North America comps: any sign of deceleration in the rate of decline?
• China Q2 revenue: on track for full-year ~20% growth target?
• SG&A: are proxy costs and one-time items cleanly excluded from forward guidance?
• Free cash flow: does trailing FCF stay above $1B for the year?
• O’Neill commentary: does her September 8 start produce any early strategic signal?
• Forward multiple: does the stock stay below 12x on revised estimates, or does a guidance cut push it above?

Bottom Line

If inventory units are falling, full-price sales are rising sequentially, and FY26 EPS guidance holds at or above $9.70, then LULU at 10-11 times earnings is genuinely cheap for a brand with more than $1 billion in annual free cash flow and a direct-to-consumer model that still works in China. If any two of those three conditions fail on September 3, the low multiple is a symptom, not a bargain.